Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 22, 2020 09:00 ET | Source: Jounce Therapeutics, Inc.

Jounce Therapeutics Presents First Preclinical Data on Anti-CCR8 Antibody JTX-1811 and Vopratelimab Translational Data at The American Association for Cancer Research Virtual Annual Meeting

- Preclinical data supports the development of JTX-1811, targeting CCR8, as a novel immunotherapy for the selective depletion of immunosuppressive tumor-infiltrating T-regulatory cells - -...
June 18, 2019 08:00 ET | Source: Jounce Therapeutics, Inc.

Jounce Therapeutics Initiates Phase 2 EMERGE Study of Vopratelimab in Combination with Ipilimumab in Patients with Non-Small Cell Lung Cancer or Urothelial Cancer

- Commenced patient enrollment in Phase 2 clinical trial of vopratelimab in combination with ipilimumab - - Preliminary efficacy and relationship to biomarker data expected in 2020 - CAMBRIDGE,...
January 03, 2019 08:00 ET | Source: Jounce Therapeutics, Inc.

Jounce Therapeutics Completed Enrollment in First Cohort of Phase 1 Clinical Trial with its PD-1 Inhibitor, JTX-4014

CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...